A landmark Alzheimer’s drug approval would likely deepen racial inequities in dementia care
Approval of Biogen’s aducanumab would likely only increase massive racial inequities in the treatment of the more than 6 million Americans with Alzheimer’s.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
